Sanofi Share Price Nasdaq

Equities

SNY

US80105N1054

Pharmaceuticals

Market Closed - Nasdaq 01:30:00 27/04/2024 am IST 5-day change 1st Jan Change
49.13 USD -0.47% Intraday chart for Sanofi +6.11% -1.21%

Financials

Sales 2024 * 45.99B 49.17B 4,101B Sales 2025 * 49.79B 53.24B 4,441B Capitalization 114B 122B 10,159B
Net income 2024 * 6.86B 7.33B 612B Net income 2025 * 8.62B 9.21B 768B EV / Sales 2024 * 2.6 x
Net Debt 2024 * 5.65B 6.04B 504B Net Debt 2025 * 2.37B 2.53B 211B EV / Sales 2025 * 2.34 x
P/E ratio 2024 *
16.4 x
P/E ratio 2025 *
13.3 x
Employees 86,088
Yield 2024 *
4.15%
Yield 2025 *
4.46%
Free-Float 87.01%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.47%
1 week+6.11%
Current month+1.09%
1 month-1.25%
3 months-2.01%
6 months-7.88%
Current year-1.21%
More quotes
1 week
46.12
Extreme 46.12
49.83
1 month
45.22
Extreme 45.22
49.83
Current year
45.22
Extreme 45.22
52.79
1 year
42.63
Extreme 42.63
55.93
3 years
36.91
Extreme 36.91
58.10
5 years
36.91
Extreme 36.91
58.10
10 years
36.81
Extreme 36.8101
58.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 01/19/01
Chief Operating Officer 39 01/22/01
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 01/14/01
Director/Board Member 64 22/20/22
Director/Board Member 52 28/20/28
More insiders
Name Weight AuM 1st Jan change Investor Rating
1.56% 9 M€ -4.31% -
More ETFs positioned on Sanofi
Date Price Change Volume
26/24/26 49.13 -0.47% 4,148,180
25/24/25 49.36 +5.90% 6,469,838
24/24/24 46.61 -2.26% 1,662,201
23/24/23 47.69 +1.15% 1,664,860
22/24/22 47.15 +1.84% 2,086,303

Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST

More quotes
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
91.23 EUR
Average target price
107.9 EUR
Spread / Average Target
+18.26%
Consensus